In this issue of Heart Failure Clinics, guest editors Drs. Alberto M. Marra, Pietro Ameri, and
Alexander E. Sherman bring their considerable expertise to Challenges in Pulmonary …

Abstract Treatment for pulmonary arterial hypertension (PAH) has evolved over the past
decade, including approval of new medications and growing evidence to support earlier use …

Background Since the initial description in the 1980s, our understanding of the diversity of
pulmonary arterial hypertension (PAH) has continued to evolve. In this study, we report the …

Pulmonary arterial hypertension (PAH) is a rare chronic vascular disease characterized by
progressive pulmonary vascular resistance (PVR), leading to right ventricular (RV) failure …

Dr. Sahay's primary research interest is group 1 PH. He currently serves as the principal
investigator (PI) on multiple clinical trials involving pulmonary vascular diseases and has …

Frantz Anticoagulation in PAH: Further Evidence REVEALed 2361 deserves further study, is
yet another reason supporting efforts to halt the slide in autopsy rates, and is a call for …

Rationale: Prior research suggests that there are geographic differences in mortality in
individuals with pulmonary arterial hypertension, even after adjusting for sociodemographic …

The American philosopher and writer Ralph Waldo Emerson once said,'How much of human
life is lost in waiting! Let him not make his fellow creatures wait'. 1 By the time patients with …

arterial hypertension (IPAH, previously identified as primary pulmonary hypertension) was
originally characterized as a disease of younger adults, more frequently women, and …

Background: Pulmonary hypertension is a complication of chronic lung diseases (PH-CLD)
associated with significant morbidity and mortality. Management guidelines for PH-CLD …